ROCEPHIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROCEPHIN (ROCEPHIN).
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
| Metabolism | Ceftriaxone is not metabolized in the liver; it is eliminated primarily via renal and biliary routes. Approximately 33-67% of the dose is excreted unchanged in the urine, and the remainder is excreted in the feces via bile. |
| Excretion | Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal. |
| Half-life | Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly. |
| Protein binding | 95% bound, primarily to albumin. |
| Volume of Distribution | 0.12-0.14 L/kg; reflects moderate tissue distribution, not extensive due to high protein binding. |
| Bioavailability | IM: 100% bioavailability; IV: 100%. |
| Onset of Action | IV: Immediate; IM: 1-2 hours after injection. |
| Duration of Action | Approximately 24 hours; allows once-daily dosing due to prolonged half-life and high protein binding. |
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR <10 mL/min: 1 g every 24 hours; no adjustment for GFR >=10 mL/min. |
| Liver impairment | No adjustment required for Child-Pugh A or B; insufficient data for Child-Pugh C; monitor if severe impairment. |
| Pediatric use | 50-75 mg/kg IV or IM once daily; maximum 2 g/day. For meningitis: 100 mg/kg once daily (max 4 g). |
| Geriatric use | No specific adjustment; dose based on renal function (creatinine clearance) as per adult guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROCEPHIN (ROCEPHIN).
| Breastfeeding | Ceftriaxone is excreted into human breast milk in low concentrations (M/P ratio approximately 0.04). It is considered compatible with breastfeeding by the American Academy of Pediatrics. Caution should be exercised as it may alter infant gut flora. |
| Teratogenic Risk | Ceftriaxone crosses the placenta. Animal studies at doses up to 20 times the human dose showed no evidence of teratogenicity. In humans, large epidemiological studies have not demonstrated an increased risk of major birth defects after first-trimester exposure. However, because animal reproduction studies are not always predictive of human response, ceftriaxone should be used during pregnancy only if clearly needed. No known fetal risks in any trimester. |
■ FDA Black Box Warning
Anaphylactic reactions: Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients on penicillin therapy. Before therapy with ceftriaxone is instituted, careful inquiry should be made concerning previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs.
| Serious Effects |
["Hypersensitivity to ceftriaxone, any cephalosporin, or any component of the formulation.","Hyperbilirubinemic neonates (especially those premature) due to risk of kernicterus.","Neonates (≤28 days) receiving calcium-containing IV solutions (risk of fatal ceftriaxone-calcium precipitates)."]
| Precautions | ["Hypersensitivity reactions: Cross-allergenicity with penicillins and other beta-lactams.","Gallbladder pseudolithiasis: Ceftriaxone-calcium precipitates may form, causing biliary sludge or stones.","Clostridioides difficile-associated diarrhea (CDAD): May range from mild diarrhea to fatal colitis.","Hemolytic anemia: Immune-mediated hemolytic anemia reported, often fatal; discontinue if anemia develops.","Neonates: Risk of bilirubin encephalopathy due to displacement of bilirubin from albumin; avoid in hyperbilirubinemic neonates.","Calcium-containing solutions: Avoid coadministration with calcium-containing IV solutions in neonates due to risk of fatal precipitation."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for maternal allergic reactions, signs of superinfection, and for neonatal jaundice if used near term (ceftriaxone can displace bilirubin from albumin). |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data on fertility impairment. |